demonstrated that, relative to the ad libitum group, the CR group showed markedly higher levels of bone resorption markers (CTX and TRAP5b), accompanied by a notable decrease in the bone formation marker bone-specific alkaline phosphatase (BAP)
Participants received therapy for 56 weeks, followed by a 26-week follow-up period
Take it seriously - it's a practical interaction-risk advisory specific to this category, not standard boilerplate
Regulators cannot verify whether a vial actually contains the ingredient named on the label, whether the stated concentration is accurate, or whether the substance was manufactured, stored and transported under the rigorous conditions required for sterile injectables
The drugs can have unsavory side effects, most frequently nausea
In parallel, the landscape of pharmacological therapies for T2DM and (to a lesser extent) obesity has expanded in recent decades with new classes of molecules coming into the market
